Topically Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic Patients Undergoing Foot and Ankle Surgery

Dane K. Wukich, Jeffrey W. Dikis, Spencer J. Monaco, Kristin Strannigan, Natalie C. Suder, Bedda L. Rosario

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: The purpose of this study was to evaluate the efficacy of topically applied vancomycin powder in reducing the rate of surgical site infections (SSIs) in patients with diabetes mellitus (DM) undergoing foot and ankle surgery. Methods: Eighty-one patients with DM who underwent reconstructive surgery of a foot and/or ankle deformity and/or trauma and who received topically applied vancomycin were matched to 81 patients with DM who did not receive topically applied vancomycin. The mean age was 60.6 years in the vancomycin group and 59.4 years in the control group (P <.05). The 2 groups were similar with regard to gender, body mass index, duration of DM, short-term and longer term glycemic control, and length of surgery. Results: The overall likelihood of SSI was decreased by 73% in patients who received topically applied vancomycin (odds ratio [OR], 0.267; 95% CI, 0.089-0.803; P =.0188). The rate of superficial infection was not significantly different between the 2 groups (OR, 0.400; 95% CI, 0.078-2.062; P =.2734); however, deep infections were 80% less likely in patients who received vancomycin powder (OR, 0.200; 95% CI, 0.044-0.913; P =.0377). Conclusion: High-risk diabetic patients undergoing foot and ankle surgery were notably less likely to develop an SSI with the use of topically applied vancomycin powder in the surgical wound, particularly with regard to deep infections. Topically applied vancomycin was associated with a very low rate of complications and was inexpensive ($5 per 1000 mg). Based on this study, foot and ankle surgeons may consider applying 500 to 1000 mg of vancomycin powder prior to skin closure in diabetic patients who are not allergic to vancomycin. Level of Evidence: Level III, retrospective case control series.

Original languageEnglish (US)
Pages (from-to)1017-1024
Number of pages8
JournalFoot and Ankle International
Volume36
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

Surgical Wound Infection
Vancomycin
Ankle
Powders
Foot
Diabetes Mellitus
Odds Ratio
Reconstructive Surgical Procedures
Infection
Body Mass Index

Keywords

  • antibiotics
  • diabetes
  • neuropathy
  • postoperative

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Topically Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic Patients Undergoing Foot and Ankle Surgery. / Wukich, Dane K.; Dikis, Jeffrey W.; Monaco, Spencer J.; Strannigan, Kristin; Suder, Natalie C.; Rosario, Bedda L.

In: Foot and Ankle International, Vol. 36, No. 9, 01.01.2015, p. 1017-1024.

Research output: Contribution to journalArticle

Wukich, Dane K. ; Dikis, Jeffrey W. ; Monaco, Spencer J. ; Strannigan, Kristin ; Suder, Natalie C. ; Rosario, Bedda L. / Topically Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic Patients Undergoing Foot and Ankle Surgery. In: Foot and Ankle International. 2015 ; Vol. 36, No. 9. pp. 1017-1024.
@article{86d0c2d3440a46cca8fdf5d52ac529af,
title = "Topically Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic Patients Undergoing Foot and Ankle Surgery",
abstract = "Background: The purpose of this study was to evaluate the efficacy of topically applied vancomycin powder in reducing the rate of surgical site infections (SSIs) in patients with diabetes mellitus (DM) undergoing foot and ankle surgery. Methods: Eighty-one patients with DM who underwent reconstructive surgery of a foot and/or ankle deformity and/or trauma and who received topically applied vancomycin were matched to 81 patients with DM who did not receive topically applied vancomycin. The mean age was 60.6 years in the vancomycin group and 59.4 years in the control group (P <.05). The 2 groups were similar with regard to gender, body mass index, duration of DM, short-term and longer term glycemic control, and length of surgery. Results: The overall likelihood of SSI was decreased by 73{\%} in patients who received topically applied vancomycin (odds ratio [OR], 0.267; 95{\%} CI, 0.089-0.803; P =.0188). The rate of superficial infection was not significantly different between the 2 groups (OR, 0.400; 95{\%} CI, 0.078-2.062; P =.2734); however, deep infections were 80{\%} less likely in patients who received vancomycin powder (OR, 0.200; 95{\%} CI, 0.044-0.913; P =.0377). Conclusion: High-risk diabetic patients undergoing foot and ankle surgery were notably less likely to develop an SSI with the use of topically applied vancomycin powder in the surgical wound, particularly with regard to deep infections. Topically applied vancomycin was associated with a very low rate of complications and was inexpensive ($5 per 1000 mg). Based on this study, foot and ankle surgeons may consider applying 500 to 1000 mg of vancomycin powder prior to skin closure in diabetic patients who are not allergic to vancomycin. Level of Evidence: Level III, retrospective case control series.",
keywords = "antibiotics, diabetes, neuropathy, postoperative",
author = "Wukich, {Dane K.} and Dikis, {Jeffrey W.} and Monaco, {Spencer J.} and Kristin Strannigan and Suder, {Natalie C.} and Rosario, {Bedda L.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1071100715586567",
language = "English (US)",
volume = "36",
pages = "1017--1024",
journal = "Foot and Ankle International",
issn = "1071-1007",
publisher = "AOFAS - American Orthopaedic Foot and Ankle Society",
number = "9",

}

TY - JOUR

T1 - Topically Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic Patients Undergoing Foot and Ankle Surgery

AU - Wukich, Dane K.

AU - Dikis, Jeffrey W.

AU - Monaco, Spencer J.

AU - Strannigan, Kristin

AU - Suder, Natalie C.

AU - Rosario, Bedda L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: The purpose of this study was to evaluate the efficacy of topically applied vancomycin powder in reducing the rate of surgical site infections (SSIs) in patients with diabetes mellitus (DM) undergoing foot and ankle surgery. Methods: Eighty-one patients with DM who underwent reconstructive surgery of a foot and/or ankle deformity and/or trauma and who received topically applied vancomycin were matched to 81 patients with DM who did not receive topically applied vancomycin. The mean age was 60.6 years in the vancomycin group and 59.4 years in the control group (P <.05). The 2 groups were similar with regard to gender, body mass index, duration of DM, short-term and longer term glycemic control, and length of surgery. Results: The overall likelihood of SSI was decreased by 73% in patients who received topically applied vancomycin (odds ratio [OR], 0.267; 95% CI, 0.089-0.803; P =.0188). The rate of superficial infection was not significantly different between the 2 groups (OR, 0.400; 95% CI, 0.078-2.062; P =.2734); however, deep infections were 80% less likely in patients who received vancomycin powder (OR, 0.200; 95% CI, 0.044-0.913; P =.0377). Conclusion: High-risk diabetic patients undergoing foot and ankle surgery were notably less likely to develop an SSI with the use of topically applied vancomycin powder in the surgical wound, particularly with regard to deep infections. Topically applied vancomycin was associated with a very low rate of complications and was inexpensive ($5 per 1000 mg). Based on this study, foot and ankle surgeons may consider applying 500 to 1000 mg of vancomycin powder prior to skin closure in diabetic patients who are not allergic to vancomycin. Level of Evidence: Level III, retrospective case control series.

AB - Background: The purpose of this study was to evaluate the efficacy of topically applied vancomycin powder in reducing the rate of surgical site infections (SSIs) in patients with diabetes mellitus (DM) undergoing foot and ankle surgery. Methods: Eighty-one patients with DM who underwent reconstructive surgery of a foot and/or ankle deformity and/or trauma and who received topically applied vancomycin were matched to 81 patients with DM who did not receive topically applied vancomycin. The mean age was 60.6 years in the vancomycin group and 59.4 years in the control group (P <.05). The 2 groups were similar with regard to gender, body mass index, duration of DM, short-term and longer term glycemic control, and length of surgery. Results: The overall likelihood of SSI was decreased by 73% in patients who received topically applied vancomycin (odds ratio [OR], 0.267; 95% CI, 0.089-0.803; P =.0188). The rate of superficial infection was not significantly different between the 2 groups (OR, 0.400; 95% CI, 0.078-2.062; P =.2734); however, deep infections were 80% less likely in patients who received vancomycin powder (OR, 0.200; 95% CI, 0.044-0.913; P =.0377). Conclusion: High-risk diabetic patients undergoing foot and ankle surgery were notably less likely to develop an SSI with the use of topically applied vancomycin powder in the surgical wound, particularly with regard to deep infections. Topically applied vancomycin was associated with a very low rate of complications and was inexpensive ($5 per 1000 mg). Based on this study, foot and ankle surgeons may consider applying 500 to 1000 mg of vancomycin powder prior to skin closure in diabetic patients who are not allergic to vancomycin. Level of Evidence: Level III, retrospective case control series.

KW - antibiotics

KW - diabetes

KW - neuropathy

KW - postoperative

UR - http://www.scopus.com/inward/record.url?scp=84940768505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940768505&partnerID=8YFLogxK

U2 - 10.1177/1071100715586567

DO - 10.1177/1071100715586567

M3 - Article

VL - 36

SP - 1017

EP - 1024

JO - Foot and Ankle International

JF - Foot and Ankle International

SN - 1071-1007

IS - 9

ER -